GlassScriptPhysician profile
Philip Joson
NPI 1275595548
$5,867.22
in general payments reported to CMS, 2019-2025
28 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $610 · 2021: $834 · 2022: $975 · 2023: $978 · 2024: $1,402 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,672 · Education: $34.25 · Gift: $20.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,671.70 |
| Education | $34.25 |
| Gift | $20.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,275.65 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $813.87 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $547.72 | 2019-2025 | |
| Janssen Biotech, INC. | $403.13 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $358.34 | 2019-2024 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $270.41 | 2024-2025 | Voquezna |
| Celgene Corporation | $241.00 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $147.97 | 2019-2024 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $128.25 | 2019-2024 | |
| Qol Medical, LLC | $92.49 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $76.43 | 2019-2024 | Ocaliva |
| Redhill Biopharma INC. | $71.52 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $59.62 | 2020-2024 | Dificid |
| Ardelyx, INC. | $52.86 | 2022-2024 | Ibsrela |
| Daiichi Sankyo INC. | $40.31 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $34.25 | 2024 | Zymfentra |
| Gilead Sciences, INC. | $32.82 | 2019-2021 | |
| Allergan, INC. | $31.79 | 2019 | |
| Amgen INC. | $27.44 | 2023 | Amjevita, Avsola |
| Genzyme Corporation | $23.67 | 2022 | |
| Madrigal Pharmaceuticals | $21.48 | 2024 | Resmetirom |
| Organon LLC | $19.92 | 2024 | |
| Ferring Pharmaceuticals INC. | $18.67 | 2019 | |
| Vivus LLC | $18.58 | 2023 | Qsymia |
| Lilly USA, LLC | $17.80 | 2024 | Omvoh |
| Boston Scientific Corporation | $17.54 | 2023 | |
| Shionogi INC | $11.99 | 2019 | |
| Alfasigma USA, INC. | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Joson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.